Accelerate Diagnostics to Present at the 35th Annual J.P. Morgan Healthcare Conference
December 14 2016 - 7:00AM
Accelerate Diagnostics, Inc. announced today that it will present
at the 35th Annual J.P. Morgan Healthcare Conference in San
Francisco, CA on Wednesday, January 11, 2017 at 11:00 a.m. PT.
A live audio webcast of the presentation will be accessible from
the investor portal of the company’s website at
axdx.com/investors.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (“Accelerate Diagnostics”)
(Nasdaq:AXDX), is an in vitro diagnostics company dedicated to
providing solutions for the global challenge of antibiotic
resistance and hospital acquired infections. The company's fully
automated Accelerate Pheno™ system, and direct from positive blood
culture Accelerate PhenoTest™ BC kit, leverage a suite of
technologies to eliminate the lengthy culture and sample
preparation steps required prior to testing. Using proprietary
molecular and phenotypic detection methods, the solution aims to
reduce the time that clinicians must wait for quantitative
antimicrobial susceptibility results necessary for optimal
antibiotic selection, dosing, and infusion strategy, called minimum
inhibitory concentrations, or MICs. The Accelerate Pheno™ system
and Accelerate PhenoTest™ BC kit are currently under review by the
U.S. Food and Drug Administration.
Visit axdx.com to get more information about Accelerate
Diagnostics and its products and technologies.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and
“ACCELERATE PHENOTEST” logos and marks are trademarks or registered
trademarks of Accelerate Diagnostics, Inc.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, about our projections as to
when certain key business milestones may be achieved, including
obtaining marketing authorization by the FDA of the Accelerate
Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood
cultures, the commercial launch of the Accelerate Pheno™ system and
Accelerate PhenoTest™ BC kit for positive blood cultures, the
potential of our technology, the growth of the market, our
estimates as to the size of our market opportunity and potential
pricing, our competitive position and estimates of time reduction
to results, and our future development plans and growth strategy.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements.
Information about the risks and uncertainties faced by Accelerate
Diagnostics is contained in the section captioned “Risk Factors” in
the company's most recent Annual Report on Form 10-K, filed with
the Securities and Exchange Commission on March 9, 2016. In
addition, the company's forward-looking statements could be
affected by general industry and market conditions. Except as
required by federal securities laws, the company undertakes no
obligation to update or revise these forward-looking statements to
reflect new events, uncertainties or other contingencies.
Investors May Contact:
Laura Pierson, Accelerate Diagnostics, +1 520 365-3100
investors@axdx.com
Reporters May Contact:
Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100
achasteen@axdx.com
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Sep 2023 to Sep 2024